Data Published Shows Efficiency and Accuracy of Gene Expression Assay Technology
Complete the form below to unlock access to ALL audio articles.
HTG Inc. has announced results from a study measuring gene expression on marker genes have been published in the August 2006 issue of Toxicology in Vitro.
The study examined the feasibility of obtaining higher throughput results using the quantitative Nuclease Protection Assay (qNPAT) method versus the standard PCR-based testing approach in testing 12 specific gene markers of drug-induced phospholipidosis on HepG2 cells.
The published data show that the in vitro screening assay for compound-induced phospholipidosis should be transferable from a PCR-based assay to HTG's qNPA, a higher throughput method.
Hiroshi Sawada, Takeda Pharmaceutical Company Limited in Osaka, Japan is the lead author of the article.
The article entitled, "Improved Toxicogenomic Screening for Drug-Induced Phospholipidosis Using a Multiplexed Quantitative Gene Expression ArrayPlate assay," reports outcomes from a follow-on study to a toxicogenomics analysis evaluated in previous research that enables researchers to identify sets of gene markers for various toxic conditions.
These findings published in Toxicology in Vitro, the official journal of the European Society of Toxicology in Vitro, confirm the qNPA approach is beneficial in setting up toxicogenomics-based assay systems to further evaluate these gene markers.
The qNPA was tested on the following measures: sensitivity, repeatability and correlation.
Results demonstrated the expression of mRNA for all target genes was detected at quantifiable levels, the signal intensities and fold change values of each marker gene were highly repeatable and there was a high correlation between results gained from the qNPA and real-time PCR assays.
"We are thrilled Takeda recognizes the qNPA technology as a useful, investigative tool in evaluating toxicogenomics analysis," said Bill Radany, president and CEO, HTG.
"HTG is enabling high-throughput screening for mainstream drug discovery and is a cost effective alternative to PCR."
HTG's ArrayPlate qNPAT technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
HTG's ArrayPlate lysis-only quantitative Nuclease Protection Assay (qNPAT) platform is designed to allow scientists to test any sample while avoiding the need for extraction or target amplification.
The platform is designed to provide high-quality quantitative test results, including QSAR-quality dose response data and EC50's.
